Wechselwirkungen · Dovprela (previously Pretomanid FGK)
Dovprela 200 mg tablet · Abschnitt 4.5 · PDF-Seite 6
HOS-144820 · Präparat HOS-099268
In vitro studies indicate that pretomanid is an inhibitor of BCRP, OATP1B3 and P-gp. No clinical studies have been performed to investigate these interactions. Therefore, it cannot be excluded that co-administration of pretomanid with sensitive OATP1B3 substrates (e.g., valsartan, statins), BCRP substrates (e.g. rosuvastatin, prazosin, glyburide, sulfasalazine) and P-gp substrates (e.g. digoxin, dabigatran etexilate, verapamil) may increase their exposure. If pretomanid is co-administered with substrates of OATP1B3, BCRP or P-gp, monitoring for drug-related adverse reactions to the co- administered medicinal product should be performed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfasalazine (HOS-089673) prazosin (HOS-127968) rosuvastatin (HOS-086307) digoxin (HOS-086172) glyburide (HOS-109273) valsartan (HOS-088810) dabigatran etexilate (HOS-086233) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-14T16:46:00Z · SHA-256 f4a7f0a8b4df86dce72356ee9b9c725ab35f6da93524ade713723e655c07a01c · Passage bfae030b8ad85409a88192aea0eb66eb46f2e062a994c086920760155c36e5e7 · Zeichen 2090–2734 im Abschnitt